Skip to main content
. 2020 Feb 10;6(1):18–26. doi: 10.1016/j.cdtm.2019.12.008

Table 2.

Baseline characteristics of participants included in the meta-analysis.

References Group Gender (M/F) Mean age UTP (g/24 h)
SCr (μmol/L)
Baseline End point Baseline End point
Chen 201219 ACEI/ARBs 11/14 56.90 ± 12.10 8.57 ± 0.53 7.10 ± 0.79 125.60 ± 29.42 127.60 ± 31.3
ACEI/ARBs + TG 12/13 57.30 ± 11.60 8.34 ± 1.29 6.42 ± 0.95 131.12 ± 27.21 129.6 ± 26.13
Song 200520 ACEI/ARBs 22/10 53.10 ± 11.30 1.65 ± 0.62 1.23 ± 0.53 85.77 ± 19.10 88.15 ± 17.13
ACEI/ARBs + TG 21/14 50.10 ± 10.50 1.63 ± 0.51 0.88 ± 0.31 83.15 ± 20.56 70.56 ± 17.32
He 201621 ACEI/ARBs 25/10 58.50 ± 6.80 2.56 ± 0.57 1.97 ± 0.39
ACEI/ARBs + TG 24/11 57.80 ± 6.90 2.55 ± 0.57 1.38 ± 0.20
Zhang 201222 ACEI/ARBs 35/15 54.23 ± 8.23 1.71 ± 0.15 1.25 ± 0.14 125.90 ± 27.50 118.30 ± 26.40
ACEI/ARBs + TG 33/17 53.66 ± 7.80 1.73 ± 0.16 0.89 ± 0.12 128.40 ± 27.60 105.70 ± 22.70
Tu 201723 ACEI/ARBs 62/46 52.30 ± 6.30 1.44 ± 0.28 0.73 ± 0.24 127.99 ± 25.44 110.62 ± 20.35
ACEI/ARBs + TG 66/42 51.20 ± 5.90 1.43 ± 0.29 0.47 ± 0.24 126.96 ± 24.40 101.31 ± 20.29
Wu 201824 ACEI/ARBs 18/16 55.00 ± 8.00 4.00 ± 1.70 3.00 ± 1.60 137.00 ± 50.00 125.00 ± 46.00
ACEI/ARBs + TG 19/15 55.00 ± 9.00 4.00 ± 2.10 1.70 ± 1.20 133.00 ± 51.00 104.00 ± 42.00
Zhang 201625 ACEI/ARBs 40/30 59.82 ± 6.79 4.65 ± 2.93 3.50 ± 1.95 199.70 ± 65.83 235.96 ± 73.45
ACEI/ARBs + TG 46/24 59.94 ± 6.53 4.68 ± 2.57 1.44 ± 1.03 198.35 ± 63.94 210.35 ± 68.50
Li 201526 ACEI/ARBs 17/13 56.12 ± 10.34 2.65 ± 1.32 2.29 ± 0.10 147.31 ± 28.62 145.25 ± 29.10
ACEI/ARBs + TG 16/14 55.37 ± 9.97 2.74 ± 1.43 1.47 ± 0.69 145.78 ± 24.79 140.12 ± 23.16
Song 201427 ACEI/ARBs 24/16 50.33 ± 5.32 2.43 ± 1.04 1.98 ± 0.93 101.42 ± 31.35 105.32 ± 38.32
ACEI/ARBs + TG 22/18 51.24 ± 5.77 2.54 ± 1.21 1.82 ± 0.89 102.48 ± 29.45 109.87 ± 41.43

M/F: male/female; UTP: urine total protein; SCr: serum creatinine; ACEI: angiotensin-converting enzyme inhibitor; ARBs: angiotensin receptor blockers; TG: Tripterygium glycoside.